Contrarius Group Holdings Ltd Purchases Shares of 368,811 CRISPR Therapeutics AG (NASDAQ:CRSP)

Contrarius Group Holdings Ltd purchased a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 368,811 shares of the company's stock, valued at approximately $14,516,000. CRISPR Therapeutics comprises about 0.9% of Contrarius Group Holdings Ltd's portfolio, making the stock its 23rd biggest position. Contrarius Group Holdings Ltd owned 0.43% of CRISPR Therapeutics at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in CRSP. Magnetar Financial LLC acquired a new position in CRISPR Therapeutics during the fourth quarter worth $359,000. Teacher Retirement System of Texas boosted its stake in shares of CRISPR Therapeutics by 18.5% during the 4th quarter. Teacher Retirement System of Texas now owns 23,969 shares of the company's stock worth $943,000 after buying an additional 3,736 shares during the last quarter. Koss Olinger Consulting LLC grew its holdings in shares of CRISPR Therapeutics by 115.3% in the 4th quarter. Koss Olinger Consulting LLC now owns 34,168 shares of the company's stock valued at $1,345,000 after acquiring an additional 18,298 shares in the last quarter. Privium Fund Management B.V. raised its holdings in CRISPR Therapeutics by 15.3% during the fourth quarter. Privium Fund Management B.V. now owns 34,997 shares of the company's stock worth $1,377,000 after acquiring an additional 4,650 shares in the last quarter. Finally, Horizon Kinetics Asset Management LLC boosted its position in CRISPR Therapeutics by 4.3% during the fourth quarter. Horizon Kinetics Asset Management LLC now owns 10,682 shares of the company's stock valued at $420,000 after purchasing an additional 443 shares during the last quarter. 69.20% of the stock is owned by institutional investors.

Remove Ads

Insider Buying and Selling

In other news, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the transaction, the chief executive officer now owns 171,613 shares in the company, valued at approximately $9,473,037.60. This trade represents a 9.66 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel James R. Kasinger sold 2,850 shares of the company's stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $120,897.00. Following the sale, the general counsel now owns 77,530 shares of the company's stock, valued at approximately $3,288,822.60. This represents a 3.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,381 shares of company stock worth $1,608,243. Corporate insiders own 4.10% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on CRSP shares. Stifel Nicolaus dropped their price objective on CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating on the stock in a research note on Thursday, February 13th. Citigroup cut their price target on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating for the company in a research note on Tuesday, February 18th. Evercore ISI raised shares of CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and upped their target price for the company from $60.00 to $99.00 in a report on Friday, February 14th. HC Wainwright reiterated a "buy" rating and set a $65.00 price target on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Finally, Truist Financial upped their price objective on CRISPR Therapeutics from $100.00 to $120.00 and gave the company a "buy" rating in a research note on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $73.11.

CRISPR Therapeutics Stock Up 3.4 %

Shares of NASDAQ:CRSP traded up $1.40 during trading on Monday, reaching $42.62. 1,339,755 shares of the company traded hands, compared to its average volume of 1,527,002. The firm has a market capitalization of $3.66 billion, a PE ratio of -9.75 and a beta of 1.77. CRISPR Therapeutics AG has a 52 week low of $36.52 and a 52 week high of $73.09. The company's 50 day moving average is $43.09 and its two-hundred day moving average is $45.37.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, research analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.